A5016092330- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Cancer, Lipids, and Metabolism
- Bladder and Urothelial Cancer Treatments
- Radiomics and Machine Learning in Medical Imaging
- PARP inhibition in cancer therapy
- Nausea and vomiting management
- Multiple Myeloma Research and Treatments
- Cancer Genomics and Diagnostics
- Chemotherapy-related skin toxicity
- Cancer Diagnosis and Treatment
- Urinary and Genital Oncology Studies
- Immunodeficiency and Autoimmune Disorders
- Artificial Intelligence in Healthcare and Education
- Peptidase Inhibition and Analysis
- Childhood Cancer Survivors' Quality of Life
- COVID-19 diagnosis using AI
- Extracellular vesicles in disease
- Infectious Diseases and Tuberculosis
- Family and Patient Care in Intensive Care Units
- Medical Imaging Techniques and Applications
- Palliative Care and End-of-Life Issues
Mayo Clinic in Arizona
2016-2025
Mayo Clinic
2017-2024
Health First
2023
Mayo Clinic in Florida
2023
Mayo Clinic Hospital
2023
WinnMed
2022-2023
University of Siena
2021
Azienda Ospedaliera Universitaria Senese
2021
University of Alabama at Birmingham
2013
Vanderbilt University
2010
The field of theranostics is rapidly advancing, driven by the goals enhancing patient care. Recent breakthroughs in artificial intelligence (AI) and its innovative theranostic applications have marked a critical step forward nuclear medicine, leading to significant paradigm shift precision oncology. For instance, AI-assisted tumor characterization, including automated image interpretation, segmentation, feature identification, prediction high-risk lesions, improves diagnostic processes,...
Background Many patients use artificial intelligence (AI) chatbots as a rapid source of health information. This raises important questions about the reliability and effectiveness AI in delivering accurate understandable Purpose To evaluate compare accuracy, conciseness, readability responses from OpenAI ChatGPT-4 Google Bard to patient inquiries concerning novel 177 Lu-PSMA-617 therapy for prostate cancer. Materials methods Two experts listed 12 most commonly asked by on therapy. These...
Abstract Purpose: Two randomized clinical trials (STOMP and ORIOLE) demonstrated that stereotactic ablative radiotherapy (SABR) can prolong ADT-free survival or progression-free (PFS) in patients with metachronous oligometastatic prostate cancer (omCSPC) patients. While most omCSPC have a more modest delay progression, small subset achieves durable response following SABR. We investigated the prognostic predictive value of circulating PSMA-positive extracellular vesicles (PSMA+EV) specific...
524 Background: Antiangiogenic tyrosine kinase inhibitors (TKIs) play a key role in treating renal cell carcinoma and other solid organ malignancies, but TKIs cause bothersome side effects that frequently necessitate dose reductions or treatment holds. Olanzapine has been useful for palliating symptoms from classical chemotherapies advanced cancer, its effect on TKI-related is largely unknown. This retrospective study aimed to estimate the efficacy of olanzapine TKI-induced nausea, vomiting,...
112 Background: We now have more than a decade of experience using Androgen Receptor Pathway Inhibitors (ARPIs) across various disease states prostate cancer, and the safety their combination with Lutetium-177–PSMA-617 has been demonstrated in VISION other large randomized clinical trials. However, real-world data on treatment patterns outcomes involving therapies 177 Lu-PSMA-617 remain limited. Methods: For this analysis, we utilized Mayo Clinic Rochester radiopharmaceutical database,...
129 Background: Few studies have explored the use of focal therapies to address select sites resistant disease in men receiving 177-Lu-PSMA-617 for metastatic castrate prostate cancer (mCRPC). Our institutional practice is offer SBRT patients with up 5 oligoprogression or non-responding lesions while undergoing 177Lu-PSMA-617 (every 6 weeks cycles total). This determined by PSMA choline PET imaging during course 177Lu-PSMA-617. Herein, we evaluated safety adding target treatment Methods:...
114 Background: Oncologists have traditionally relied upon serial assessments of PSA and periodic imaging (i.e., every 2 to 3 cycles) monitor treatment response. Early identification disease progression allows for faster transitions alternative therapies that might be more effective. In this study, we evaluated the utility post-treatment SPECT/CT earlier detection failure in patients receiving Lutetium-177–PSMA-617 (LuPSMA). Methods: We queried an IRB-approved registry including all starting...
132 Background: Distant metastasis at the time of prostate cancer (PCa) diagnosis is associated with increased morbidity and mortality. This study aimed to assess impact sociodemographic characteristics on distant PCa diagnosis. Methods: The Surveillance Epidemiology End Results (SEER) database (2000-2021), including patients from 17 registries, was queried. Patients late-stage (LSD) were defined as those who initially diagnosed stage IV disease, indicating metastasis. Sociodemographic...
134 Background: Prostate cancer patients with visceral metastases at diagnosis are often treated using one-size-fits-all approach. For example, CHAARTED criteria treats any metastasis as high volume. Therefore, we aimed to assess overall survival (OS) by site of involvement in metastatic PCa. Methods: Surveillance, Epidemiology, and End Results (SEER) database (2010-2021) was queried obtain case listing data on PCa from 17 registries. The were categorized into three groups based diagnosis:...
261 Background: Clinicians use next-generation sequencing (NGS) to tailor targeted treatments for PCa patients. However, the results are often available in unstructured formats and saturated with technical jargon, making them inaccessible Therefore, we aimed assess efficacy of LLMs accurately extract genomic characteristics from reports generate patient-friendly summaries ease variant interpretation Methods: This retrospective study included patients who underwent NGS 2023-2024. The GPT4...
745 Background: The combination of EV-P therapy has recently been approved as first-line (1L) for patients with LA/mUC based on the results EV-302 trial. Herein, we report updated from a cohort who received in real world clinical setting. Methods: This retrospective study included (07/2022-08/2024) at Mayo Clinic completed least one cycle EV-P. best overall response (BOR) was evaluated using radiographic imaging and adjudicated complete (CR), partial (PR), stable disease (SD), mixed (MR), or...
184 Background: We update evidence on mHSPC when new becomes available (PMID: 36862387). ARANOTE trial prompted us to assess the comparative efficacy of darolutamide (DARO) with other ARPi agents in using living network meta-analysis (LNMA). Methods: This LNMA is conducted interactive (LIvE) synthesis framework. Phase III trials assessing systemic treatments are included. Mixed treatment comparisons were made a frequentist meta-analysis. P-scores computed relative rankings higher values...
341 Background: Specialist clinicians (oncologists, urologists, radiation oncologists) read through free text reports of prostate MRI and biopsy to risk stratify patients during initial consultation localized PCa. This laborious time-consuming process is repeated for each day the clinic. Herein, we propose a hybrid stratification framework utilizing combination large language model (LLM) rule-based programming automate this process. Methods: retrospective study included with PCa (2004-2024)...
136 Background: The ECOG performance status (PS) is a critical measure for evaluating functional capacity and determining clinical trial eligibility in patients with advanced prostate cancer. We aim to assess the capability of large language models (LLMs) accurately infer PS from unstructured oncology notes. Methods: This retrospective study included metastatic castration-resistant cancer (mCRPC) receiving Lutetium-177–PSMA-617 ( 177 Lu) at Mayo Clinic (2022-2023). Baseline scores were...
Abstract Immune checkpoint inhibitors (ICI) are effective for advanced melanoma. However, most develop ICI resistance. Tumor-derived soluble PD-L1 (sPD-L1) and other immunosuppressive factors drive We hypothesized that therapeutic plasma exchange (TPE) may remove sPD-L1 from circulation overcome Patients with metastatic ICI-resistant melanoma elevated received radiotherapy to a minority of lesions, TPE, re-challenge. Primary endpoints were adverse events reduction. Secondary included overall...
<p>Progression-free survival stratified by number of lesions treated</p>
<p>Progression-free survival stratified by baseline PSA DT levels</p>
<p>Progression-free survival stratified by baseline PSA and PSMA+EV</p>